Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 29 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.42 Insider Own39.68% Shs Outstand98.77M Perf Week-6.51%
Market Cap807.86M Forward P/E- EPS next Y-1.67 Insider Trans-0.14% Shs Float60.61M Perf Month-13.46%
Income-138.57M PEG- EPS next Q-0.40 Inst Own37.35% Short Float2.91% Perf Quarter-22.99%
Sales6.91M P/S116.91 EPS this Y-1.15% Inst Trans0.05% Short Ratio8.34 Perf Half Y23.69%
Book/sh2.14 P/B3.75 EPS next Y-5.42% ROA-37.86% Short Interest1.76M Perf Year86.11%
Cash/sh2.29 P/C3.51 EPS next 5Y- ROE-54.51% 52W Range4.30 - 12.45 Perf YTD1.01%
Dividend Est.- P/FCF- EPS past 5Y- ROI-46.08% 52W High-35.42% Beta1.36
Dividend TTM- Quick Ratio10.37 Sales past 5Y0.00% Gross Margin86.08% 52W Low86.98% ATR (14)0.53
Dividend Ex-Date- Current Ratio10.37 EPS Y/Y TTM36.78% Oper. Margin-2295.79% RSI (14)31.58 Volatility4.89% 5.72%
Employees76 Debt/Eq0.40 Sales Y/Y TTM- Profit Margin-2004.62% Recom1.50 Target Price14.25
Option/ShortYes / Yes LT Debt/Eq0.40 EPS Q/Q29.37% Payout- Rel Volume0.59 Prev Close8.10
Sales Surprise- EPS Surprise10.86% Sales Q/Q- EarningsMay 13 AMC Avg Volume211.38K Price8.04
SMA20-10.59% SMA50-20.06% SMA200-1.53% Trades Volume124,090 Change-0.74%
Date Action Analyst Rating Change Price Target Change
Nov-15-23Upgrade Jefferies Hold → Buy $4 → $11
Oct-26-23Upgrade Morgan Stanley Underweight → Equal-Weight $4 → $8
Jun-21-23Initiated Evercore ISI Outperform
Jun-12-23Initiated Guggenheim Buy $9
Mar-17-23Initiated SVB Securities Outperform $6
Aug-12-22Downgrade Morgan Stanley Overweight → Underweight $10 → $5
Jun-17-22Initiated BMO Capital Markets Outperform $19
Jun-03-22Downgrade Jefferies Buy → Hold $37 → $4
Feb-11-22Initiated Goldman Neutral $12
May-28-24 09:35AM
May-21-24 08:45AM
May-13-24 09:54PM
Apr-24-24 04:47AM
09:36PM Loading…
Apr-23-24 09:36PM
Apr-22-24 07:00AM
Mar-28-24 11:53PM
Mar-27-24 01:26AM
Mar-18-24 08:01PM
Feb-22-24 08:00AM
07:00AM Loading…
Feb-09-24 07:00AM
Jan-22-24 08:00AM
Dec-13-23 08:00AM
Dec-10-23 12:05PM
Dec-05-23 09:55AM
Nov-27-23 04:15PM
Nov-16-23 09:55AM
Nov-14-23 07:28PM
Nov-13-23 04:05PM
Nov-02-23 09:09AM
Oct-31-23 08:00AM
Oct-30-23 08:00AM
Oct-25-23 08:00AM
Oct-03-23 08:00AM
Sep-04-23 10:51AM
08:00AM Loading…
Aug-31-23 08:00AM
Aug-23-23 05:08PM
Aug-14-23 07:00AM
Jul-10-23 08:00AM
May-24-23 08:00AM
May-22-23 07:00AM
May-12-23 07:00AM
Apr-27-23 12:07PM
Mar-30-23 07:00AM
Mar-27-23 08:00AM
Mar-23-23 04:30PM
Mar-01-23 08:00AM
Feb-06-23 08:00AM
Feb-02-23 08:00AM
Jan-26-23 09:08AM
Dec-10-22 03:30PM
Nov-30-22 08:00AM
Nov-18-22 10:29AM
Nov-10-22 07:00AM
Nov-03-22 09:04AM
Oct-31-22 08:00AM
Sep-20-22 08:33AM
Sep-14-22 09:00AM
Sep-12-22 07:00AM
Aug-29-22 08:00AM
Aug-10-22 08:37AM
Jul-29-22 05:00AM
Jul-25-22 08:00AM
Jul-01-22 08:40AM
Jun-23-22 09:55AM
Jun-17-22 02:35PM
Jun-11-22 10:06AM
Jun-06-22 08:00AM
Jun-05-22 07:00AM
Jun-03-22 08:29AM
Jun-02-22 06:29AM
May-16-22 07:00AM
Mar-30-22 04:01PM
Mar-23-22 04:30PM
Mar-07-22 07:30AM
Feb-24-22 07:30AM
Feb-17-22 02:38AM
Jan-01-22 07:33AM
Dec-21-21 06:38PM
Dec-14-21 07:30AM
Dec-13-21 04:15PM
Dec-06-21 05:00PM
Nov-24-21 06:59AM
Nov-15-21 07:00AM
Nov-10-21 04:45PM
Nov-01-21 07:29PM
Oct-18-21 08:00AM
Oct-05-21 08:00AM
Oct-04-21 08:00AM
Sep-29-21 08:47AM
Sep-09-21 12:01PM
Sep-01-21 04:15PM
Aug-16-21 07:00AM
Jul-14-21 08:06AM
Jun-07-21 04:15PM
Jun-04-21 04:15PM
May-27-21 10:49PM
Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. Its portfolio include preclinical to phase three uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. The company was founded on October 26, 2020 and is headquartered in Altrincham, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Anderson Karen M.Chief People OfficerMar 25 '24Option Exercise3.9445,000177,252122,685Mar 26 04:16 PM
Anderson Karen M.Chief People OfficerMar 25 '24Sale11.8851,160607,96071,525Mar 26 04:16 PM
Rotman HarrisSVP Regulatory AffairsFeb 01 '24Sale8.104,26734,57462,625Feb 02 05:03 PM
Rotman HarrisSVP Regulatory AffairsSep 20 '23Option Exercise4.3737,484163,68870,984Sep 22 04:47 PM
Rotman HarrisSVP Regulatory AffairsSep 20 '23Sale6.2937,484235,68833,500Sep 22 04:47 PM
YVER ANTOINEEVP & Chairman of DevelopmentJun 01 '23Sale4.456,50028,949783,066Jun 02 05:01 PM